Mexico Admits That Hundreds Of HIV-Positive Mexicans Were Being Treated With Obsolete And Ineffective Medications
For a long time, it was considered that Mexico had averted the worst of the HIV/AIDS crisis that has plagued much of the Americas. For a country of its size and population, Mexico historically has had a very low incidence rate of HIV infection – even among populations considered at a high-risk.
Mexico is also a nation that has a robust public healthcare system that provides medical care to its citizens free-of-charge or at very low prices, including HIV medications.
Many looked to Mexico as a role model for developing countries confronting the worldwide HIV epidemic. However, after recent reports about obsolete medications being given to HIV and AIDS patients many are beginning to question that way of thinking.
Mexico’s Health ministry revealed that Mexico had been buying outdated medications from suppliers that no longer worked.
Hugo López-Gatell, Undersecretary of the Ministry of Health, revealed this morning that some drug providers were selling outdated and obsolete HIV drugs to the federal government. Many of the drug being used by the government to treat HIV-positive patients were from the 1980s and have been proven ineffective around the world.
At a press conference, he explained that in late 2019, authorities realized that drug companies were intentionally manipulating the public bidding process in a scheme to sell outdated drugs to the public health ministry.
“The combination of medicines tells us about the enormous lack of proper HIV treatment because they [the HIV medications] are not adequate. In many cases we found the use of old medicines, we found the use of the first HIV drug that was invented or discovered at the beginning of the 80s. It is a drug that is already obsolete worldwide and in Mexico was still being used,” he said.
According to the government, however, it was the fault of the drug companies that were gaming a public health system.
“What did we find?” That here were pressures from representatives of the pharmaceutical industry. We discovered that it was one group who made the medicines and that there were very few who distributed them. But they tie up the government with exclusive agreements to the different companies that manufacture the medicines,” he explained.
So basically, the distributors put pressure on doctors who specifically prescribed retroviral medications. He also clarified that purchases have always been made at the national level, however, they made no sense with the amounts of what they asked for in each state.
Despite this troubling revelation, the Ministry of Health has restated its commitment to securing the best care for those in need of HIV treatment.
The undersecretary added: “In May, we completely modified the HIV treatment scheme. First, we made it clear that we wanted the best medications, the most effective, the safest; second, we identified how many people could have this ideal medication scheme and it turns out that there were many more than those who were taking advantage of it.”
This latest news comes just months after the country reformed its HIV treatment regime, leaving many fearful of shortages.
Public health officials warned of the possibility that thousands of Mexicans who rely on HIV treatment could be left without life-saving services after the government changed the way it funds treatment.
Reforms announced last month to centralize drug procurement risk sparking shortages, they say, while the government counters that it has ample supplies and hopes its changes will save money and cut corruption in the drug buying process. It’s these reforms they say that will help combat problems such as being sold outdated and obsolete drugs.
However, many HIV activists warn of a public health crisis.
In February, the government also said that it would no longer fund civil society organizations, leaving more than 200 groups fighting the disease without resources for core activities, such as HIV testing.
Notice any needed corrections? Please email us at firstname.lastname@example.org